New Brunswick Scientific, an Eppendorf Company, and Pall Corporation have announced a joint product development and marketing agreement to create and supply new disposable bioreactor systems.
The joint effort will build on the capabilities of Pall’s Allegro™ single-use biocontainer platform and New Brunswick’s CelliGen® bioprocess controller, to better serve upstream applications ranging from the process development laboratory to the full-scale cGMP production suite.
This partnership combines the historic market strengths of the two companies in upstream biopharmaceutical processing, strengths that have been recently augmented by New Brunswick Scientific’s development of the CelliGen BLU Single-Use Stirred-Tank Bioreactor, and Pall’s acquisition of MicroReactor Technologies and the Micro-24 microbioreactor.
According to Mike Sattan, New Brunswick’s Vice President Marketing, “This is an exciting step forward, as the new system will enable us to offer an even broader range of bioreactor technology options, while we continue to provide a control system with the reliability, ease of use and configurability that our customers have come to expect.” Ken Frank, President Pall Life Sciences Biopharmaceuticals, said, “We are delighted to be able to partner with New Brunswick to extend our Allegro single-use technology to cover the entire range of upstream bioprocessing applications. We believe these new bioreactor systems will provide our customers with greater benefits in operational simplicity, product quality assurance, and process economics.”
New Brunswick Scientific, Edison, NJ 08817. www.nbsc.com or call 800-631-5417
Pall Life Sciences, Port Washington, NY 11050. www.pall.com or call 800-645-6532
